Fi3 FINANCIAL ADVISORS LLC Acquires 15,725 Shares of Mesoblast Limited (NASDAQ:MESO)

Fi3 FINANCIAL ADVISORS LLC grew its holdings in Mesoblast Limited (NASDAQ:MESO) by 75.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,625 shares of the company’s stock after acquiring an additional 15,725 shares during the quarter. Fi3 FINANCIAL ADVISORS LLC’s holdings in Mesoblast were worth $725,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of MESO. Strategic Financial Concepts LLC bought a new stake in shares of Mesoblast in the fourth quarter valued at approximately $2,744,000. Jane Street Group LLC lifted its position in Mesoblast by 46.4% in the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after purchasing an additional 26,959 shares during the period. Clayton Financial Group LLC bought a new position in Mesoblast in the fourth quarter worth $275,000. Ballentine Partners LLC bought a new position in Mesoblast in the fourth quarter worth $222,000. Finally, Sageworth Trust Co bought a new position in Mesoblast in the fourth quarter worth $198,000. 1.43% of the stock is owned by institutional investors.

Mesoblast Price Performance

Mesoblast stock opened at $13.94 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The stock has a fifty day moving average price of $16.66 and a two-hundred day moving average price of $12.86. Mesoblast Limited has a 52-week low of $2.05 and a 52-week high of $22.00.

Analyst Upgrades and Downgrades

MESO has been the subject of several research reports. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a research report on Tuesday, March 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $24.00 target price (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Finally, Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Mesoblast presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.